This study is performed on healthy volunteers..
Conditions
Interventions
Intervention 1: Intervention group: Single-dose ofFinerenone 20 mg tablets - Obidi Pharmaceutical Company in the first period. Cross-over design with one week washing period. Intervention 2: Interven
Sponsors
Abidi Pharmaceutical Company
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: General health (liver, heart, kidney) of volunteers Informed consent form Body mass index range (18-30) Age between18-55
Exclusion criteria
Exclusion criteria: Smoking Having a history of cardiovascular disease Having a history of liver & kidney disease Having a Alcohol & Drug addiction Having a hypersensitivity to the drug Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concentration of the drug in blood. Timepoint: 0 ,0.33 , 0.66 , 1, 1.33 , 1.66 , 2 , 3 , 4 , 6 , 8 , 12 h after drug administration. Method of measurement: Liquid Chromatography with Mass-Mass Detector. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to reach maximum blood concentration. Timepoint: After intervention. Method of measurement: The time to reach the maximum drug concentration in blood is recorded.;Extent of absorption. Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Shokri
Tabriz University of Medical Sciences
Outcome results
None listed